Celecoxib, celebrex® (DrugBank: Celecoxib)
9 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
2 | Amyotrophic lateral sclerosis | 0 |
3 | Spinal muscular atrophy | 0 |
34 | Neurofibromatosis | 0 |
46 | Malignant rheumatoid arthritis | 0 |
70 | Spinal stenosis | 0 |
89 | Lymphangioleiomyomatosis | 0 |
161 | Familial benign chronic pemphigus | 0 |
171 | Wilson disease | 0 |
271 | Ankylosing spondylitis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01709656 (ClinicalTrials.gov) | March 2012 | 10/10/2012 | A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis | A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis | Ankylosing Spondylitis | Biological: MSC;Drug: celecoxib, Celebrex® | Sun Yat-sen University | NULL | Completed | 16 Years | 65 Years | Both | 120 | N/A | China |